DexCom Inc. Q1 2024 10-Q Filing
Ticker: DXCM · Form: 10-Q · Filed: 2024-04-25T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, medical-devices
Related Tickers: AMZN, GOOG, MSFT
TL;DR
DexCom's Q1 2024 10-Q is in, check the latest financials.
AI Summary
DexCom Inc. filed its 10-Q for the quarter ending March 31, 2024, reporting on its financial performance. The company's fiscal year ends on December 31st, and this filing covers the first quarter of 2024. Key financial data and balance sheet information for the periods ending March 31, 2024, and December 31, 2023, are detailed.
Why It Matters
This filing provides investors and analysts with the latest financial snapshot of DexCom, Inc., crucial for understanding the company's current financial health and performance trends in the medical device sector.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2024 Q1 — Reporting Period (First quarter of 2024 financial results)
- 12/31 — Fiscal Year End (Indicates the company's annual reporting cycle)
Key Players & Entities
- DexCom Inc. (company) — Filer of the 10-Q
- 20240331 (date) — End of the reporting period
- 20240425 (date) — Filing date
- 2023-12-31 (date) — Previous year-end reporting date
FAQ
What is the primary purpose of this 10-Q filing?
This 10-Q filing provides DexCom Inc.'s quarterly financial statements and management's discussion and analysis for the period ending March 31, 2024.
What is the filing date for this 10-Q?
The filing date for this 10-Q is April 25, 2024.
What is DexCom Inc.'s fiscal year end?
DexCom Inc.'s fiscal year ends on December 31st.
What specific financial periods are covered by the balance sheet information in this filing?
The balance sheet information covers the periods ending March 31, 2024, and December 31, 2023.
What is the Standard Industrial Classification (SIC) code for DexCom Inc.?
The SIC code for DexCom Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
From the Filing
0001093557-24-000079.txt : 20240425 0001093557-24-000079.hdr.sgml : 20240425 20240425171702 ACCESSION NUMBER: 0001093557-24-000079 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 24877504 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 dxcm-20240331.htm 10-Q dxcm-20240331 false 2024 Q1 0001093557 12/31 0.0243476 0.0061571 0.006662 365 390 365 0001093557 2024-01-01 2024-03-31 0001093557 2024-04-18 xbrli:shares 0001093557 2024-03-31 iso4217:USD 0001093557 2023-12-31 iso4217:USD xbrli:shares 0001093557 2023-01-01 2023-03-31 0001093557 us-gaap:CommonStockMember 2023-12-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001093557 us-gaap:RetainedEarningsMember 2023-12-31 0001093557 us-gaap:TreasuryStockCommonMember 2023-12-31 0001093557 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001093557 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001093557 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001093557 us-gaap:CommonStockMember 2024-03-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001093557 us-gaap:RetainedEarningsMember 2024-03-31 0001093557 us-gaap:TreasuryStockCommonMember 2024-03-31 0001093557 us-gaap:CommonStockMember 2022-12-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001093557 us-gaap:RetainedEarningsMember 2022-12-31 0001093557 us-gaap:TreasuryStockCommonMember 2022-12-31 0001093557 2022-12-31 0001093557 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001093557 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001093557 us-gaap:CommonStockMember 2023-03-31 0001093557 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001093557 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001093557 us-gaap:RetainedEarningsMember 2023-03-31 0001093557 us-gaap:TreasuryStockCommonMember 2023-03-31 0001093557 2023-03-31 0001093557 srt:MinimumMember 2024-01-01 2024-03-31 0001093557 srt:MaximumMember 2024-01-01 2024-03-31 0001093557 dxcm:CollaborativeSalesBasedMilestoneMember 2024-01-01 2024-03-31 0001093557 dxcm:CollaborativeSalesBasedMilestoneMember 2023-01-01 2023-03-31 0001093557 dxcm:RestrictedAndPerformanceStockUnitsMember 2024-01-01 2024-03-31 0001093557 dxcm:RestrictedAndPerformanceStockUnitsMember 2023-01-01 2023-03-31 0001093557 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-03-31 0001093557 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001093557 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001093557 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001093557 dxcm:VerilyLifeSciencesMember dxcm:CollaborativeArrangementInitialPaymentMember us-gaap:CollaborativeArrangementMember 2018-12-28 0001093557 dxcm:VerilyLifeSciencesMember dxcm:CollaborativeArrangementInitialPaymentMember us-gaap:CollaborativeArrangementMember 2018-12-31 0001093557 dxcm:VerilyLifeSciencesMember dxcm:Collabora